Cisapride (R 51619): A Benchmark 5-HT4 Agonist and hERG Channel Inhibitor for Cardiac Electrophysiology Research

Executive Summary: Cisapride (R 51619) is a chemically defined nonselective 5-HT4 receptor agonist and a potent inhibitor of the hERG potassium channel, making it essential for cardiac electrophysiology and predictive cardiotoxicity studies (Grafton et al., 2021). The compound is supplied at ≥99.70% purity by APExBIO and is stable as a solid at −20°C (APExBIO product page). It dissolves at ≥23.3 mg/mL in DMSO and ≥3.47 mg/mL in ethanol, but is insoluble in water. Cisapride is widely used to benchmark hERG blockade in iPSC-derived cardiomyocyte models, supporting high-content screening and deep learning approaches for early drug safety de-risking (Grafton et al., 2021). Correct handling and assay integration are critical to avoid confounds in cardiotoxicity and motility studies.

Biological Rationale

Cisapride (R 51619) targets two key pathways in human physiology. First, it acts as a nonselective 5-HT4 receptor agonist, modulating serotonergic signaling, which is relevant for gastrointestinal motility and cardiac function (APExBIO). Second, Cisapride is a potent inhibitor of the human ether-à-go-go-related gene (hERG) potassium channel. hERG channel blockade can prolong cardiac repolarization, manifesting as QT interval prolongation and increasing arrhythmogenic risk (Grafton et al., 2021). Because drug-induced hERG inhibition is a leading cause of clinical trial failures and drug withdrawals, Cisapride is instrumental in modeling and benchmarking these liabilities in vitro (see also: Precision Tool for hERG and 5-HT4).

Mechanism of Action of Cisapride (R 51619)

Cisapride (R 51619) binds to the 5-HT4 receptor, acting as an agonist to enhance downstream cAMP signaling and promote motility in gastrointestinal tissues (APExBIO). In cardiac myocytes, it inhibits the hERG (KCNH2) potassium channel, reducing I_Kr current and delaying repolarization. This dual mechanism underpins its dual use in both gastrointestinal and cardiac models but also underlies its arrhythmia risk profile. High-affinity hERG inhibition by Cisapride is dose-dependent and reproducible in cell-based assays.

Evidence & Benchmarks

• Cisapride is a validated reference compound for hERG channel inhibition in iPSC-derived cardiomyocyte models, reproducing classic QT-prolonging effects (Grafton et al. 2021, https://doi.org/10.7554/eLife.68714).
• Deep learning-enabled high-content imaging can detect Cisapride-induced cardiotoxic phenotypes with high sensitivity and specificity (Grafton et al. 2021, https://doi.org/10.7554/eLife.68714).
• Cisapride (R 51619) displays solubility at ≥23.3 mg/mL in DMSO and ≥3.47 mg/mL in ethanol, but is insoluble in water, ensuring reproducibility in in vitro assays (APExBIO, product details).
• Quality control for APExBIO's Cisapride includes HPLC, NMR, and MSDS, ensuring ≥99.70% purity and batch-to-batch consistency (https://www.apexbt.com/cisapride.html).
• Comparative studies show Cisapride's predictive value for arrhythmogenic risk, outperforming less selective 5-HT4 agonists in phenotypic screening (Optimizing Cardiotoxicity and Cell Assays).

Applications, Limits & Misconceptions

Cisapride is most commonly employed in:

• Cardiac electrophysiology research, especially for modeling hERG channel inhibition and arrhythmogenesis.
• Phenotypic screening of compounds using iPSC-derived cardiomyocytes with deep learning image analysis (Grafton et al., 2021).
• 5-HT4 receptor pathway studies in gastrointestinal motility models.

For a comprehensive guide to protocol integration, see Optimizing Cardiotoxicity and Cell Assays (this article extends coverage by detailing specific solubility, storage, and QC parameters critical for assay reproducibility).

Common Pitfalls or Misconceptions

• Cisapride's insolubility in water precludes its direct use in aqueous assays without suitable co-solvents (e.g., DMSO, ethanol).
• It is not selective for hERG over other cardiac channels, so off-target effects can confound results if not properly controlled.
• Long-term storage of Cisapride solutions is not recommended; instability may alter potency or introduce degradation products.
• Cisapride should not be used to infer selective 5-HT4 receptor effects in tissues where hERG is also expressed.
• Dose selection must account for differential sensitivity across cell types and assay formats.

Workflow Integration & Parameters

For optimal use, Cisapride (R 51619) from APExBIO (SKU B1198) should be handled as follows:

• Store solid compound at -20°C; prepare fresh solutions for each experiment.
• Dissolve in DMSO (≥23.3 mg/mL) or ethanol (≥3.47 mg/mL); avoid water as a solvent.
• Incorporate Cisapride at concentrations validated for the specific cell type and assay (e.g., 0.1–10 μM for hERG inhibition in iPSC-CMs).
• Ensure batch-to-batch quality by referencing HPLC and NMR reports supplied by APExBIO.
• For high-content screening and deep learning workflows, use Cisapride as a positive control to calibrate phenotypic thresholds and assess assay dynamic range (see Transforming Cardiac Electrophysiology for integration examples; this article provides more granular QC/solubility data).

Conclusion & Outlook

Cisapride (R 51619) remains a reference standard for interrogating 5-HT4 receptor signaling and hERG channel blockade in cardiac electrophysiology research. As advanced in vitro models and AI-enabled screening methods proliferate, the need for rigorously characterized compounds like Cisapride from APExBIO is paramount. Researchers are encouraged to leverage the detailed product documentation and validated workflows to ensure robust, reproducible results in both phenotypic and mechanistic assays. For ordering details and documentation, visit the Cisapride (R 51619) product page.